WWM
AIMT

Willingdon Wealth Management’s Aimmune Therapeutics AIMT Stock Holding History

Willingdon Wealth Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-7
Closed – – 567
2019
Q3 		$0 Buy
+7
New +$143 ﹤0.01% 555

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Willingdon Wealth Management's AIMT Position: Q4 2019 in Review

Willingdon Wealth Management sold out of Aimmune Therapeutics (AIMT) in Q4 2019, closing a stake of 7 shares.

Willingdon Wealth Management first reported a position in AIMT in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 155 funds tracked by Wall St. Rank hold AIMT as of Q4 2019.

  • Willingdon Wealth Management reported no remaining Aimmune Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Willingdon Wealth Management sold 7 Aimmune Therapeutics shares in Q4 2019.
  • Willingdon Wealth Management first reported a position in Aimmune Therapeutics in Q3 2019 and held it in 1 quarter.
  • Willingdon Wealth Management's Aimmune Therapeutics position peaked at $0 in Q3 2019.
  • 155 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2019.

Based on Willingdon Wealth Management's 13F filing for Q4 2019, filed 10 Feb 2020.